P
Plethico Pharmaceuticals Ltd
PLETHICO
Plethico Pharmaceuticals Ltd
Healthcare Pharmaceuticals & Biotechnology
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Plethico Pharmaceuticals Ltd insights
29 extracted metrics + investor summaries across FY07–FY14.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company has reduced debt.
- Stock is trading at 0.02 times its book value
Weaknesses
6- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 9.07% over last 3 years.
- Contingent liabilities of Rs.1,518 Cr.
- Company has high debtors of 198 days.
- Company's cost of borrowing seems high
Growth Rate
Revenue Growth
-52.00% →
Net Income Growth
-56.00% →
Cash Flow Change
-
ROE
7.00% ↗
ROCE
-
EBITDA Margin (Avg.)
-
Quarterly Results
| Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 490 | 480 | 447 | 364 | 310 | 278 | 263 | 111 | 113 |
| Expenses | 459 | 403 | 392 | 265 | 262 | 227 | 211 | 93 | 120 |
| Operating Profit | 32 | 77 | 54 | 100 | 48 | 51 | 52 | 18 | -7 |
| OPM % | 7% | 16% | 12% | 27% | 16% | 18% | 20% | 16% | -6% |
| Other Income | 3 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | -320 |
| Interest | 15 | 35 | 23 | 29 | 57 | 36 | 52 | 12 | 22 |
| Depreciation | 4 | 10 | 7 | 27 | 16 | 15 | 15 | 11 | 16 |
| PBT | 16 | 38 | 24 | 43 | -24 | -1 | -15 | -4 | -365 |
| Tax % | 16% | -18% | 14% | -2% | -51% | 34% | -59% | 0% | -27% |
| Net Profit | 13 | 44 | 21 | 44 | -12 | -2 | -6 | -4 | -266 |
| EPS in Rs | 3.88 | 13.03 | 6.16 | 12.94 | -3.52 | -0.49 | -1.85 | -1.19 | -77.99 |
Profit & Loss
| Sep 2006 | Dec 2007 15m | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 15m | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 366 | 549 | 905 | 1,249 | 1,529 | 1,557 | 1,632 | 2,060 | 765 |
| Expenses | 272 | 410 | 774 | 1,014 | 1,191 | 1,342 | 1,470 | 1,766 | 652 |
| Operating Profit | 93 | 140 | 131 | 235 | 338 | 215 | 161 | 294 | 113 |
| OPM % | 26% | 25% | 15% | 19% | 22% | 14% | 10% | 14% | 15% |
| Other Income | 10 | 38 | 16 | 27 | -2 | 23 | 33 | 42 | -320 |
| Interest | 6 | 10 | 23 | 35 | 40 | 89 | 67 | 175 | 122 |
| Depreciation | 5 | 7 | 16 | 17 | 26 | 18 | 18 | 64 | 58 |
| PBT | 92 | 161 | 109 | 210 | 269 | 131 | 109 | 97 | -386 |
| Tax % | 4% | 2% | -13% | -3% | 9% | 22% | 7% | -14% | — |
| Net Profit | 89 | 158 | 123 | 217 | 244 | 103 | 101 | 111 | -278 |
| EPS in Rs | 25.81 | 46.48 | 36.21 | 63.68 | 71.74 | 30.21 | 29.79 | 32.49 | -81.52 |
| Div. Payout % | 10% | 5% | 7% | 4% | 3% | 0% | 0% | 0% | — |
Balance Sheet
| Sep 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 |
| Reserves | 412 | 559 | 702 | 856 | 1,037 | 1,331 | 1,333 | 1,580 |
| Borrowings | 95 | 383 | 682 | 612 | 581 | 1,069 | 1,187 | 1,391 |
| Other Liabilities | 48 | 43 | 92 | 87 | 180 | 126 | 177 | 309 |
| Total Liabilities | 588 | 1,018 | 1,509 | 1,590 | 1,832 | 2,559 | 2,732 | 3,315 |
| Fixed Assets | 177 | 111 | 425 | 401 | 411 | 445 | 427 | 986 |
| CWIP | 24 | 2 | 191 | 213 | 255 | 401 | 395 | 0 |
| Investments | 43 | 409 | 199 | 199 | 199 | 199 | 199 | 199 |
| Other Assets | 344 | 496 | 694 | 776 | 967 | 1,514 | 1,711 | 2,130 |
| Total Assets | 588 | 1,018 | 1,509 | 1,590 | 1,832 | 2,559 | 2,732 | 3,315 |
Cash Flow
| Sep 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|
| Operating | -39 | 70 | 138 | 165 | 176 | -272 | -61 | 244 |
| Investing | -39 | -255 | -409 | -14 | -101 | -15 | 23 | -490 |
| Financing | 146 | 266 | 167 | -147 | -85 | 357 | -40 | 249 |
| Net Cash Flow | 68 | 81 | -105 | 4 | -10 | 70 | -79 | 2 |
| Free Cash Flow | -65 | 67 | -248 | 152 | 91 | -373 | -56 | -386 |
| CFO/OP | -36 | 50 | 115 | 64 | 55 | -118 | -43 | 78 |
Ratios
| Sep 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 232 | 177 | 157 | 133 | 152 | 228 | 274 | 198 |
| Inventory Days | 42 | 17 | 114 | 84 | 73 | 76 | 72 | 60 |
| Days Payable | 25 | 16 | 66 | 35 | 62 | 23 | 24 | 32 |
| Cash Conversion Cycle | 249 | 177 | 205 | 181 | 163 | 281 | 322 | 225 |
| Working Capital Days | 234 | 204 | 212 | 177 | 171 | 300 | 337 | 281 |
| ROCE % | — | 20% | 17% | 17% | 20% | 14% | 7% | 10% |
Documents
Frequently Asked Questions about Plethico Pharmaceuticals Ltd
What does Plethico Pharmaceuticals Ltd do?
Plethico Pharmaceuticals Ltd is an India-based healthcare pharmaceutical company engaged in the manufacture and marketing of pharmaceutical and allied healthcare.
Where is Plethico Pharmaceuticals Ltd (PLETHICO) listed?
Plethico Pharmaceuticals Ltd is listed on the Indian stock exchanges. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Plethico Pharmaceuticals Ltd belong to?
Plethico Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
How can I research Plethico Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Plethico Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Plethico Pharmaceuticals Ltd is an India-based healthcare pharmaceutical company engaged in the manufacture and marketing of pharmaceutical and allied healthcare.
Website plethico.com
Face Value ₹ 10